Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 311

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 311
---
 on March 4, 2021 (the “Effective Date”). On March 9, 2021, the Company consummated the IPO of 27,600,000units (the “Units”), which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000Units, at $ 10.00per Unit, generating gross proceeds of $ 276,000,000, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of 5,013,333warrants (the “Private Warrants”) to the Sponsor and Cantor Fitzgerald & Co. (“Cantor”), the representative of the underwriters of the IPO, at a price of $ 1.50per Private Warrant, generating gross proceeds of $ 7,520,000, which is discussed in Note 4. Each warrant (including the Private Warrants and the warrants included as part of the Units) entitles the holder to purchase oneshare of common stock at a price of $ 11.50per share. Transaction costs for the IPO amounting to $ 15,627,893(consisting of $ 5,520,000of underwriting discount, $ 9,660,000of deferred underwriting discount, and $ 447,893of other offering costs) were recognized, of which $ 606,622was (i) allocated to the public warrants and Private Warrants and (ii) included in the statements of operations, and $ 15,021,271was charged directly to stockholders’ equity. Following the closing of the IPO on March 9, 2021, $ 276,000,000(approximately $ 10.00per Unit) from the net proceeds of the sale of the Units in the IPO, including the proceeds from the sale of the Private Warrants, was deposited in a trust account (“Trust Account”), located in the United States with Continental Stock Transfer & Trust Company acting as trustee (the “Trustee”), and was invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. In December 2022, the Company instructed the